• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

    3.450 -0.190 (-5.22%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 131,444
    Open 3.640
    Bid (Size) 3.330 (1)
    Ask (Size) 3.780 (10)
    Prev. Close 3.640
    Today's Range 3.340 - 3.820
    52wk Range 0.3900 - 8.920
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Whooping Cough Prevalence Rises in US as Missed Shots During Pandemic Come Home to Roost
    Via Investor Brand Network
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
    Via Investor Brand Network

    Performance

    YTD
    +465.85%
    +465.85%
    1 Month
    -10.34%
    -10.34%
    3 Month
    +17.35%
    +17.35%
    6 Month
    +569.25%
    +569.25%
    1 Year
    +305.88%
    +305.88%

    More News

    Read More
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
    Via Investor Brand Network
    New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
    Via Investor Brand Network
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
    Via Investor Brand Network
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
    Via Investor Brand Network
    SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
    Via InvestorPlace
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
    Via Investor Brand Network
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
    Via Investor Brand Network
    Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
    Via Investor Brand Network
    7 F-Rated Stocks for Your August 2024 Sell List
    Via InvestorPlace
    Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
    Via Investor Brand Network
    BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
    Via Investor Brand Network
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
    Via Benzinga
    Exposures Fossil Fuels
    Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition
    Via InvestorPlace
    M Stock Plunges 13% as Macy’s Calls Off Take-Private Talks
    Via InvestorPlace
    Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
    Via Benzinga
    Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
    Via InvestorPlace
    BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
    Via Investor Brand Network
    Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage
    Via Investor Brand Network
    BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
    Via Investor Brand Network
    SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.